Free Trial

Instil Bio (TIL) Competitors

Instil Bio logo
$31.60 -0.65 (-2.00%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TIL vs. PHAT, UPB, XNCR, MNMD, ABUS, EOLS, RLAY, KROS, DNA, and TYRA

Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Phathom Pharmaceuticals (PHAT), Upstream Bio (UPB), Xencor (XNCR), Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Evolus (EOLS), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Ginkgo Bioworks (DNA), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

Instil Bio vs. Its Competitors

Phathom Pharmaceuticals (NASDAQ:PHAT) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Instil Bio has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Instil Bio has lower revenue, but higher earnings than Phathom Pharmaceuticals. Instil Bio is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom Pharmaceuticals$55.25M12.07-$334.33M-$5.24-1.82
Instil BioN/AN/A-$74.14M-$11.97-2.64

Phathom Pharmaceuticals presently has a consensus price target of $17.50, suggesting a potential upside of 83.15%. Instil Bio has a consensus price target of $119.00, suggesting a potential upside of 276.64%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Phathom Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phathom Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
Instil Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Instil Bio has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -422.42%. Phathom Pharmaceuticals' return on equity of 0.00% beat Instil Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Phathom Pharmaceuticals-422.42% N/A -90.11%
Instil Bio N/A -45.52%-29.23%

In the previous week, Phathom Pharmaceuticals had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Phathom Pharmaceuticals and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Phathom Pharmaceuticals' score of 1.12 indicating that Instil Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Phathom Pharmaceuticals Positive
Instil Bio Very Positive

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 23.0% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 47.2% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals and Instil Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

MetricInstil BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$207.43M$3.04B$5.72B$9.52B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.6421.1228.0720.02
Price / SalesN/A340.60462.58104.32
Price / CashN/A43.2336.5558.97
Price / Book1.228.338.645.90
Net Income-$74.14M-$55.19M$3.24B$258.50M
7 Day Performance21.05%5.91%4.08%2.12%
1 Month Performance17.41%17.69%10.68%12.62%
1 Year Performance149.37%5.36%34.47%19.25%

Instil Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
3.1676 of 5 stars
$31.60
-2.0%
$119.00
+276.6%
+151.7%$207.43MN/A-2.64410Positive News
PHAT
Phathom Pharmaceuticals
4.31 of 5 stars
$9.06
-1.3%
$17.50
+93.2%
-21.0%$632.48M$55.25M-1.73110Positive News
UPB
Upstream Bio
1.7818 of 5 stars
$11.73
+2.2%
$56.50
+381.7%
N/A$631.00M$2.30M0.0038News Coverage
XNCR
Xencor
4.5069 of 5 stars
$8.85
+0.2%
$28.00
+216.4%
-54.7%$629.85M$110.49M-2.89280
MNMD
Mind Medicine (MindMed)
2.0021 of 5 stars
$8.33
+3.3%
$25.50
+206.1%
+11.5%$629.36MN/A-6.4640News Coverage
ABUS
Arbutus Biopharma
2.2729 of 5 stars
$3.24
+2.2%
$5.50
+69.8%
-16.3%$620.56M$6.17M-7.9090
EOLS
Evolus
3.718 of 5 stars
$9.51
+0.3%
$23.75
+149.7%
-21.5%$613.21M$266.27M-10.69170Upcoming Earnings
RLAY
Relay Therapeutics
2.6502 of 5 stars
$3.56
-1.1%
$17.67
+396.3%
-58.8%$610.36M$10.01M-1.60330News Coverage
KROS
Keros Therapeutics
2.2059 of 5 stars
$14.57
+0.9%
$30.56
+109.7%
-71.0%$591.83M$3.55M-80.94100Positive News
DNA
Ginkgo Bioworks
0.7412 of 5 stars
$9.91
-0.7%
$8.50
-14.3%
N/A$580.29M$237.42M-1.08640Positive News
TYRA
Tyra Biosciences
3.1525 of 5 stars
$10.91
+6.3%
$30.83
+182.6%
-48.6%$579.21MN/A-6.6920

Related Companies and Tools


This page (NASDAQ:TIL) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners